| Literature DB >> 34440082 |
Jin Hee Kim1, Da Hae Kim1, Youn-Hee Lim2,3, Choong Ho Shin4, Young Ah Lee4, Bung-Nyun Kim5, Johanna Inhyang Kim6, Yun-Chul Hong2,3,7.
Abstract
Childhood obesity could contribute to adulthood obesity, leading to adverse health outcomes in adults. However, the mechanisms for how obesity is developed are still unclear. To determine the epigenome-wide and genome-wide expression changes related with childhood obesity, we compared microRNome and transcriptome levels as well as leptin protein levels in whole bloods of 12 obese and 24 normal children aged 6 years. miR-328-3p, miR-1301-3p, miR-4685-3p, and miR-6803-3p were negatively associated with all obesity indicators. The four miRNAs were also associated with 3948 mRNAs, and separate 475 mRNAs (185 among 3948 mRNAs) were associated with all obesity indicators. The 2533 mRNAs (64.2%) among the 3948 mRNAs and 286 mRNAs (60.2%) among the 475 mRNAs were confirmed as targets of the four miRNAs in public databases through miRWalk 2.0. Leptin protein was associated with miR-6803-3p negatively and all obesity indicators positively. Using DAVID bioinformatics resources 6.8, top three pathways for obesity-related gene set were metabolic pathways, pathways in cancer, and PI3K-Akt signaling pathway. The top three obesity-related disease classes were metabolic, cardiovascular, and chemdependency. Our results support that childhood obesity could be developed through miRNAs-related epigenetic mechanism and, further, these obesity-related epigenetic changes could control the pathways related with the development of various diseases.Entities:
Keywords: children; disease class; mRNA; miRNA; obesity; omics; pathway
Year: 2021 PMID: 34440082 PMCID: PMC8389653 DOI: 10.3390/biomedicines9080878
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059
Characteristics of the participants.
| Characteristic, Mean ± SE (Range) or no. (%) | Obese Children ( | Normal Children ( | |
|---|---|---|---|
| Child | |||
| Age, months | 70.1 ± 0.4 (69–73) | 70.1 ± 0.3 (69–73) | 1.0 |
| Sex, no. of boys (%) | 6 (50.0) | 12 (50.0) | 1.0 |
| Weight, kg | 25.6 ± 0.8 (21.5–30.5) | 20.4 ± 0.4 (17.5–25.8) | <0.0001 |
| Height, cm | 118.5 ± 1.2 (112.3–125.1) | 115.9 ± 0.6 (111.1–124.6) | 0.0475 |
| BMI, kg/m2 | 18.2 ± 0.3 (17.0–21.1) | 15.1 ± 0.2 (13.7–17.0) | <0.0001 |
| Vigorous physical activity, mins/day | 32.5 ± 9.9 (0–120) | 41.5 ± 6.1 (0–120) | 0.4245 |
| Calorie intake, kcal/day | 1671.8 ± 129.5 (939.2–2646.4) | 1462.4 ± 66.4 (853.9–2099.9) | 0.1184 |
| Current drug use, no. (%) | |||
| No | 12 (100) | 22 (91.6) | 0.5890 |
| Flu | 0 (0) | 1 (4.2) | |
| Rhinitis | 0 (0) | 1 (4.2) | |
| Adiponectin, µg/mL | 10.2 ± 0.7 (6.0–13.2) | 9.0 ± 0.5 (5.5–17.6) | 0.1744 |
| Leptin, ng/mL | 9.2 ± 1.5 (4.0–21.8) | 5.7 ± 0.6 (3.0–15.6) | 0.0373 |
| Parent | |||
| Mother BMI (before pregnancy), kg/m2 | 21.3 ± 0.7 (16.6–25.6) | 21.1 ± 0.4 (18.1–25.4) | 0.8159 |
| Father BMI, kg/m2 | 25.3 ± 0.9 (19.6–29.8) | 25.5 ± 0.6 (21.0–31.7) | 0.8178 |
1 Student’s t-test for mean comparison and χ2 test for frequency comparison. BMI, body mass index; SE, standard error.
Associations between four miRNAs levels and three obesity indicators.
| 95% CI | |||||
|---|---|---|---|---|---|
| miRNA | Obesity Indicator | β or OR | Lower CI | Upper CI | |
| miR-328-3p | BMI | −1.83 | −3.14 | −0.52 | 0.0079 |
| miR-1301-3p | BMI | −1.79 | −3.51 | −0.08 | 0.0412 |
| miR-4685-3p | BMI | −1.49 | −2.63 | −0.35 | 0.0121 |
| miR-6803-3p | BMI | −1.30 | −2.25 | −0.35 | 0.0091 |
| miR-328-3p | BMI z-score | −1.04 | −1.85 | −0.22 | 0.0143 |
| miR-1301-3p | BMI z-score | −1.08 | −2.13 | −0.03 | 0.0444 |
| miR-4685-3p | BMI z-score | −0.89 | −1.59 | −0.19 | 0.0142 |
| miR-6803-3p | BMI z-score | −0.78 | −1.37 | −0.20 | 0.0103 |
| miR-328-3p | Obesity development | 0.04 | 0.003 | 0.59 | 0.0192 |
| miR-1301-3p | Obesity development | 0.06 | 0.004 | 0.97 | 0.0475 |
| miR-4685-3p | Obesity development | 0.07 | 0.01 | 0.62 | 0.0178 |
| miR-6803-3p | Obesity development | 0.07 | 0.01 | 0.75 | 0.0289 |
β values for BMI and BMI z-score and OR for obesity development were evaluated after adjusted for sex, age (month), calorie intake, and current disease. BMI, body mass index; OR, odds ratio; CI, confidence interval.
Figure 1Venn diagrams comparing counts of associations among 3948 mRNAs statistically associated with four obesity-associated miRNAs, 19,382 genes predicted as targets of the four obesity-associated miRNAs, and 475 mRNAs statistically associated with three obesity indicators. (a) miR-328-3p (b) miR-1301-3p (c) miR-4685-3p (d) miR-6803-3p (e) Total four miRNAs.
Relations of leptin protein with four miRNAs and three obesity indicators.
| 95% CI | |||||
|---|---|---|---|---|---|
| Independent Variable | Dependent Variable | β or OR | Lower CI | Upper CI | |
| miR-328-3p | Leptin | −1.65 | −4.80 | 1.50 | 0.2936 |
| miR-1301-3p | Leptin | −0.88 | −4.88 | 3.11 | 0.6540 |
| miR-4685-3p | Leptin | −2.01 | −4.65 | 0.64 | 0.1310 |
| miR-6803-3p | Leptin | −2.26 | −4.42 | −0.10 | 0.0413 |
| Leptin | BMI | 0.28 | 0.15 | 0.42 | 0.0002 |
| Leptin | BMI z-score | 0.15 | 0.06 | 0.24 | 0.0020 |
| Leptin | Obesity development | 1.66 | 1.09 | 2.54 | 0.0180 |
β values for relations among miRNAs, leptin, and BMI or BMI z-score and OR for leptin and obesity development were evaluated after adjusted for sex, age (month), calorie intake, and current disease. BMI, body mass index; OR, odds ratio; CI, confidence interval.
Figure 2Venn diagrams comparing counts of associations between mRNAs in Figure 1 and leptin protein-associated mRNAs. Superscripted (1) and (2) means different groups for same counts.
Figure 3Networking among four obesity-associated miRNAs, 185 mRNAs which were statistically associated with four miRNAs and three obesity indicators, and obesity representing BMI z-score with leptin using Cytoscape.
Top ten KEGG pathways related with obesity.
| miRNA Name | KEGG Pathways | No. of Database-Matched Genes | No. of Pathway-Related Targets (%) | |
|---|---|---|---|---|
| miR-328-3p | hsa01100:Metabolic pathways | 15,209 | 921 (6.1) | 0.0030 |
| hsa05200:Pathways in cancer | 15,209 | 348 (2.3) | <0.0001 | |
| hsa04151:PI3K-Akt signaling pathway | 15,209 | 281 (1.8) | 0.0001 | |
| hsa04010:MAPK signaling pathway | 15,209 | 224 (1.5) | <0.0001 | |
| hsa04080:Neuroactive ligand-receptor interaction | 15,209 | 216 (1.4) | 0.0231 | |
| hsa04144:Endocytosis | 15,209 | 213 (1.4) | <0.0001 | |
| hsa05166:HTLV-I infection | 15,209 | 211 (1.4) | 0.0001 | |
| hsa04014:Ras signaling pathway | 15,209 | 199 (1.3) | <0.0001 | |
| hsa04015:Rap1 signaling pathway | 15,209 | 180 (1.2) | <0.0001 | |
| hsa05205:Proteoglycans in cancer | 15,209 | 179 (1.2) | <0.0001 | |
| miR-1301-3p | hsa01100:Metabolic pathways | 16,121 | 980 (6.1) | 0.0074 |
| hsa05200:Pathways in cancer | 16,121 | 356 (2.2) | <0.0001 | |
| hsa04151:PI3K-Akt signaling pathway | 16,121 | 303 (1.9) | <0.0001 | |
| hsa04010:MAPK signaling pathway | 16,121 | 230 (1.4) | <0.0001 | |
| hsa04080:Neuroactive ligand-receptor interaction | 16,121 | 229 (1.4) | 0.0316 | |
| hsa04144:Endocytosis | 16,121 | 222 (1.4) | <0.0001 | |
| hsa05166:HTLV-I infection | 16,121 | 220 (1.4) | 0.0003 | |
| hsa04014:Ras signaling pathway | 16,121 | 205 (1.3) | <0.0001 | |
| hsa04060:Cytokine-cytokine receptor interaction | 16,121 | 201 (1.2) | 0.0426 | |
| hsa04510:Focal adhesion | 16,121 | 192 (1.2) | <0.0001 | |
| miR-4685-3p | hsa05200:Pathways in cancer | 13,811 | 320 (2.3) | <0.0001 |
| hsa04151:PI3K-Akt signaling pathway | 13,811 | 260 (1.9) | 0.0001 | |
| hsa04010:MAPK signaling pathway | 13,811 | 208 (1.5) | <0.0001 | |
| hsa05166:HTLV-I infection | 13,811 | 199 (1.4) | <0.0001 | |
| hsa04144:Endocytosis | 13,811 | 196 (1.4) | <0.0001 | |
| hsa04014:Ras signaling pathway | 13,811 | 186 (1.3) | <0.0001 | |
| hsa04015:Rap1 signaling pathway | 13,811 | 170 (1.2) | <0.0001 | |
| hsa05205:Proteoglycans in cancer | 13,811 | 169 (1.2) | <0.0001 | |
| hsa04510:Focal adhesion | 13,811 | 168 (1.2) | <0.0001 | |
| hsa04024:cAMP signaling pathway | 13,811 | 165 (1.2) | <0.0001 | |
| miR-6803-3p | hsa01100:Metabolic pathways | 17,852 | 1076 (6.0) | 0.0086 |
| hsa05200:Pathways in cancer | 17,852 | 379 (2.1) | <0.0001 | |
| hsa04151:PI3K-Akt signaling pathway | 17,852 | 318 (1.8) | 0.0004 | |
| hsa04080:Neuroactive ligand-receptor interaction | 17,852 | 256 (1.4) | 0.0012 | |
| hsa04010:MAPK signaling pathway | 17,852 | 251 (1.4) | <0.0001 | |
| hsa05166:HTLV-I infection | 17,852 | 237 (1.3) | 0.0004 | |
| hsa04144:Endocytosis | 17,852 | 228 (1.3) | <0.0001 | |
| hsa04014:Ras signaling pathway | 17,852 | 215 (1.2) | <0.0001 | |
| hsa04015:Rap1 signaling pathway | 17,852 | 204 (1.1) | <0.0001 | |
| hsa04810:Regulation of actin cytoskeleton | 17,852 | 202 (1.1) | <0.0001 | |
| Total | hsa01100:Metabolic pathways | 19,922 | 1173 (5.9) | <0.0001 |
| hsa05200:Pathways in cancer | 19,922 | 390 (2.0) | <0.0001 | |
| hsa04151:PI3K-Akt signaling pathway | 19,922 | 334 (1.7) | 0.0016 | |
| hsa04080:Neuroactive ligand-receptor interaction | 19,922 | 272 (1.4) | 0.0001 | |
| hsa04010:MAPK signaling pathway | 19,922 | 253 (1.3) | <0.0001 | |
| hsa05166:HTLV-I infection | 19,922 | 249 (1.2) | 0.0004 | |
| hsa04144:Endocytosis | 19,922 | 237 (1.2) | 0.0002 | |
| hsa04014:Ras signaling pathway | 19,922 | 221 (1.1) | 0.0019 | |
| hsa04810:Regulation of actin cytoskeleton | 19,922 | 208 (1.0) | 0.0001 | |
| hsa04015:Rap1 signaling pathway | 19,922 | 207 (1.0) | 0.0004 |
Top ten GAD disease classes related with obesity.
| miRNA Name | GAD Disease Classes | No. of Database-Matched Genes | No. of Disease Class-Related Targets (%) | |
|---|---|---|---|---|
| miR-328-3p | METABOLIC | 15,209 | 4014 (26.4) | <0.0001 |
| CARDIOVASCULAR | 15,209 | 3286 (21.6) | <0.0001 | |
| CHEMDEPENDENCY | 15,209 | 2919 (19.2) | <0.0001 | |
| NEUROLOGICAL | 15,209 | 2218 (14.6) | 0.0003 | |
| PHARMACOGENOMIC | 15,209 | 2178 (14.3) | <0.0001 | |
| PSYCH | 15,209 | 1573 (10.3) | <0.0001 | |
| UNKNOWN | 15,209 | 1253 (8.2) | 0.0004 | |
| OTHER | 15,209 | 1242 (8.2) | 0.0002 | |
| DEVELOPMENTAL | 15,209 | 1172 (7.7) | 0.0002 | |
| HEMATOLOGICAL | 15,209 | 1169 (7.7) | 0.0191 | |
| miR-1301-3p | METABOLIC | 16,121 | 4422 (27.4) | <0.0001 |
| CARDIOVASCULAR | 16,121 | 3565 (22.1) | <0.0001 | |
| CHEMDEPENDENCY | 16,121 | 3208 (19.9) | <0.0001 | |
| NEUROLOGICAL | 16,121 | 2396 (14.9) | <0.0001 | |
| PHARMACOGENOMIC | 16,121 | 2318 (14.4) | <0.0001 | |
| INFECTION | 16,121 | 1762 (10.9) | 0.0304 | |
| PSYCH | 16,121 | 1703 (10.6) | <0.0001 | |
| UNKNOWN | 16,121 | 1356 (8.4) | <0.0001 | |
| OTHER | 16,121 | 1332 (8.3) | 0.0003 | |
| DEVELOPMENTAL | 16,121 | 1290 (8.0) | <0.0001 | |
| miR-4685-3p | METABOLIC | 13,811 | 3686 (26.7) | 0.0001 |
| CARDIOVASCULAR | 13,811 | 3017 (21.8) | <0.0001 | |
| CHEMDEPENDENCY | 13,811 | 2752 (19.9) | <0.0001 | |
| NEUROLOGICAL | 13,811 | 2051 (14.9) | 0.0002 | |
| PHARMACOGENOMIC | 13,811 | 2006 (14.5) | <0.0001 | |
| PSYCH | 13,811 | 1448 (10.5) | <0.0001 | |
| UNKNOWN | 13,811 | 1145 (8.3) | 0.0065 | |
| OTHER | 13,811 | 1129 (8.2) | 0.0113 | |
| DEVELOPMENTAL | 13,811 | 1099 (8.0) | <0.0001 | |
| HEMATOLOGICAL | 13,811 | 1088 (7.9) | 0.0046 | |
| miR-6803-3p | METABOLIC | 17,852 | 4678 (26.2) | <0.0001 |
| CARDIOVASCULAR | 17,852 | 3773 (21.1) | <0.0001 | |
| CHEMDEPENDENCY | 17,852 | 3340 (18.7) | <0.0001 | |
| NEUROLOGICAL | 17,852 | 2546 (14.3) | 0.0069 | |
| PHARMACOGENOMIC | 17,852 | 2493 (14.0) | <0.0001 | |
| PSYCH | 17,852 | 1790 (10.0) | <0.0001 | |
| UNKNOWN | 17,852 | 1452 (8.1) | <0.0001 | |
| DEVELOPMENTAL | 17,852 | 1356 (7.6) | <0.0001 | |
| HEMATOLOGICAL | 17,852 | 1356 (7.6) | 0.0074 | |
| RENAL | 17,852 | 1288 (7.2) | <0.0001 | |
| Total | METABOLIC | 19,922 | 4959 (24.9) | <0.0001 |
| CARDIOVASCULAR | 19,922 | 4003 (20.1) | <0.0001 | |
| CHEMDEPENDENCY | 19,922 | 3524 (17.7) | <0.0001 | |
| IMMUNE | 19,922 | 2786 (14.0) | 0.0408 | |
| NEUROLOGICAL | 19,922 | 2701 (13.6) | 0.0189 | |
| PHARMACOGENOMIC | 19,922 | 2650 (13.3) | <0.0001 | |
| INFECTION | 19,922 | 2057 (10.3) | <0.0001 | |
| PSYCH | 19,922 | 1880 (9.4) | <0.0001 | |
| UNKNOWN | 19,922 | 1556 (7.8) | <0.0001 | |
| OTHER | 19,922 | 1508 (7.6) | 0.0006 |